Method for potentiating primary drugs in treating multidrug resistant disease
The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated with such cells.
1. A method for potentiating a primary drug to treat protozoa multidrug resistance comprising: exposing multidrug resistant protozoa to effective concentrations of a compound having the following formula:
where R 1 and R 1 ′ are the same or different short chained carbon based ligand; R 2 is CH 3 or C 2 H 5 and R 3 is CH 3 , and the isomeric configuration at the C-1′ chiral carbon location is “S”.
2. The method of claim 1 in which said compound comprises d-tetrandrine.
3. The method of claim 2 in which said compound is used at a dosage level of from about 100 to 300 mg per day.
4. The method of claim 1 in which said compound is used at a dosage level of from about 100 to 300 mg per day.
5. A method for treating multidrug resistant entamoeba histolytic (amoebic dysentery) comprising: exposing the multidrug resistant disease cells to effective concentrations of a compound having the following formula:
where R 1 and R 1 ′ are the same or different short chained carbon based moieties; R 2 is CH 3 or C 2 H 5 and R 3 is CH 3 or Hydrogen, and the isomeric configuration at the C-1′ chiral carbon location is “S”.
6. A method for treating multidrug resistant Leishmania comprising: exposing the multidrug resistant disease cells to effective concentrations of a compound having the following formula:
where R 1 and R 1 ′ are the same or different short chained carbon based moieties; R 2 is CH 3 or C 2 H 5 and R 3 is CH 3 , and the isomeric configuration at the C-1′ chiral carbon location is “S”.
7. A method for treating multidrug resistant AIDS pneumonia comprising: exposing the multidrug resistant disease cells to effective concentrations of a compound having the following formula:
where R 1 and R 1 ′ are the same or different short chained carbon based moieties; R 2 is CH 3 or C 2 H 5 and R 3 is CH 3 or Hydrogen, and the isomeric configuration at the C-1′ chiral carbon location is “S”.